PE20181080A1 - Anticuerpos que se unen especificamente a tl1a - Google Patents
Anticuerpos que se unen especificamente a tl1aInfo
- Publication number
- PE20181080A1 PE20181080A1 PE2018000398A PE2018000398A PE20181080A1 PE 20181080 A1 PE20181080 A1 PE 20181080A1 PE 2018000398 A PE2018000398 A PE 2018000398A PE 2018000398 A PE2018000398 A PE 2018000398A PE 20181080 A1 PE20181080 A1 PE 20181080A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
Links
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 title 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 abstract 2
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Sorting Of Articles (AREA)
Abstract
La presente invencion refiere un anticuerpo monoclonal recombinante, caracterizado porque comprende una CDR1 de la region variable de la cadena pesada que comprende la secuencia de aminoacidos de la SEQ ID N°: 15 y una region variable de cadena liviana que comprende la secuencia de aminoacidos de la SEQ ID N°: 18; una CDR2 de la region variable de la cadena pesada que comprende la secuencia de aminoacidos de la SEQ ID N°: 21, y una region variable de cadena liviana que comprende la secuencia de aminoacidos de la SEQ ID N°:19; una CDR3 de la region variable de la cadena pesada que comprende la secuencia de aminoacidos de la SEQ ID N°: 17, y una region variable de cadena liviana que comprende la secuencia de aminoacidos de la SEQ ID N°:22; caracterizado porque el anticuerpo se une especificamente al ligando tipo TNF 1A (TL1A). La presente invencion es util para el tratamiento de fibrosis pulmonar, asma, artritis, entre otras. Los anticuerpos inhiben la interaccion entre TL1A y el receptor de muerte 3 (DR3)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220442P | 2015-09-18 | 2015-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181080A1 true PE20181080A1 (es) | 2018-07-05 |
Family
ID=57043002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000398A PE20181080A1 (es) | 2015-09-18 | 2016-09-16 | Anticuerpos que se unen especificamente a tl1a |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US10138296B2 (es) |
| EP (2) | EP3350223B1 (es) |
| JP (2) | JP7013366B2 (es) |
| KR (1) | KR101998535B1 (es) |
| CN (1) | CN108137693B (es) |
| AR (1) | AR106055A1 (es) |
| AU (2) | AU2016323460B2 (es) |
| BR (2) | BR112018005407A8 (es) |
| CA (1) | CA2997015A1 (es) |
| CL (1) | CL2018000711A1 (es) |
| CO (1) | CO2018003736A2 (es) |
| CY (1) | CY1123499T1 (es) |
| DK (1) | DK3350223T3 (es) |
| EA (1) | EA201890756A1 (es) |
| ES (1) | ES2810751T3 (es) |
| HR (1) | HRP20201323T1 (es) |
| HU (1) | HUE051496T2 (es) |
| IL (1) | IL257761B2 (es) |
| LT (1) | LT3350223T (es) |
| MA (2) | MA42825B1 (es) |
| MD (1) | MD3350223T2 (es) |
| MX (1) | MX2018003185A (es) |
| PE (1) | PE20181080A1 (es) |
| PH (1) | PH12018500580B1 (es) |
| PL (1) | PL3350223T3 (es) |
| PT (1) | PT3350223T (es) |
| RS (1) | RS60703B1 (es) |
| SI (1) | SI3350223T1 (es) |
| SM (1) | SMT202000500T1 (es) |
| TW (1) | TWI703158B (es) |
| UA (1) | UA125284C2 (es) |
| WO (1) | WO2017049024A1 (es) |
| ZA (1) | ZA201801427B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
| WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| EP3383271B1 (en) * | 2015-12-04 | 2022-08-24 | University Of Iowa Research Foundation | System for screening delirium patients for the presence of encephalopathy |
| CN118773299A (zh) | 2016-03-17 | 2024-10-15 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| KR20240128132A (ko) | 2016-10-26 | 2024-08-23 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| AU2018259856B2 (en) * | 2017-04-28 | 2025-05-01 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| AU2020371725A1 (en) | 2019-10-24 | 2022-05-26 | Cedars-Sinai Medical Center | Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof |
| CN116348481A (zh) * | 2020-08-19 | 2023-06-27 | 詹森生物科技公司 | 使用工程化配体的材料和方法 |
| AU2023314780A1 (en) | 2022-07-27 | 2025-02-27 | Cephalon Llc | Anti-tl1a antibody formulations |
| WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
| WO2024239006A1 (en) | 2023-05-17 | 2024-11-21 | Genentech, Inc. | Anti-tl1a antibody therapeutic methods |
| WO2024263945A2 (en) * | 2023-06-22 | 2024-12-26 | Paragon Therapeutics, Inc. | Il-17 antibody compositions and methods of use |
| TW202511288A (zh) * | 2023-06-22 | 2025-03-16 | 美商派拉岡醫療公司 | Il-23抗體組合物及使用方法 |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
| WO2025076081A1 (en) | 2023-10-03 | 2025-04-10 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
| CN120058933A (zh) * | 2023-11-30 | 2025-05-30 | 北京智仁美博生物科技有限公司 | 抗肿瘤坏死因子样配体1a的抗体及其用途 |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| CN120424214A (zh) * | 2024-02-05 | 2025-08-05 | 三生国健药业（上海）股份有限公司 | 一种抗tl1a抗体及其制备方法和用途 |
| WO2025240922A1 (en) | 2024-05-17 | 2025-11-20 | Genentech, Inc. | Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody |
| CN119552252B (zh) * | 2025-01-16 | 2025-11-25 | 华润生物医药有限公司 | 抗tl1a抗体及其制备方法和应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| KR20060132006A (ko) | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| WO2007027751A2 (en) | 2005-08-30 | 2007-03-08 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| WO2007076465A2 (en) | 2005-12-23 | 2007-07-05 | Diadexus, Inc. | Cln248 antibody compositions and methods of use |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2009052512A2 (en) | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| KR101248422B1 (ko) | 2007-11-13 | 2013-04-09 | 테바 바이오파머수티컬스 유에스에이, 아이엔씨. | Ｔｌ１ａ에 대한 인간화된 항체 |
| WO2010118210A1 (en) | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| EP2519260A2 (en) | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| WO2012161856A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| EP2720719A4 (en) | 2011-06-15 | 2015-12-09 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS |
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| EA201591153A1 (ru) | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| CN112870368A (zh) * | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
| CN105307676A (zh) * | 2013-04-05 | 2016-02-03 | 豪夫迈·罗氏有限公司 | 抗il-4抗体和双特异性抗体及其用途 |
| CN105358713B (zh) | 2013-05-17 | 2020-02-28 | 雪松-西奈医学中心 | 与克罗恩病相关的tnfsf15和dcr3的变体 |
| WO2014186665A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
| WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| MX2016002879A (es) | 2013-09-06 | 2016-08-17 | Cedars Sinai Medical Center | Sistemas, dispositivos y metodos para la terapia anti-tl1a. |
| BR112016009797A2 (pt) | 2013-11-13 | 2017-12-05 | Bristol Myers Squibb Co | anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos |
| ES2924731T3 (es) | 2015-04-15 | 2022-10-10 | Biosearch Tech Inc | Sondas con extintor doble |
| US20180156781A1 (en) | 2015-05-15 | 2018-06-07 | Cedars-Sinai Medical Center | Models, methods and compositions for treating inflammatory bowel disease |
| HK1257443A1 (zh) | 2015-08-21 | 2019-10-18 | The Children's Hospital Of Philadelphia | 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| WO2017077715A1 (en) | 2015-11-02 | 2017-05-11 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| CN118773299A (zh) | 2016-03-17 | 2024-10-15 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| EA039084B1 (ru) | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Антитела к tl1a и их применения |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| KR102423942B1 (ko) | 2016-06-09 | 2022-07-22 | 펠리칸 테라퓨틱스, 인코포레이티드 | 항-tnfrsf25 항체 |
| KR20240128132A (ko) | 2016-10-26 | 2024-08-23 | 세다르스-신나이 메디칼 센터 | 중화 항-tl1a 단일 클론 항체 |
| US10626180B2 (en) | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| LT3774897T (lt) | 2018-04-30 | 2023-11-10 | Cedars-Sinai Medical Center | Pacientų, sergančių uždegiminėmis ligomis, atrankos ir gydymo būdai bei sistemos |
| WO2020113116A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| WO2021081365A1 (en) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2021108694A1 (en) | 2019-11-27 | 2021-06-03 | Cedars-Sinai Medical Center | Predicting extraintestinal manifestations of inflammatory bowel disease |
| EP4162076A4 (en) | 2020-06-03 | 2024-10-02 | Cedars-Sinai Medical Center | TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| US20230287499A1 (en) | 2020-06-03 | 2023-09-14 | Cedars-Sinai Medical Center | Methods and systems for measuring post-operative disease recurrence |
| MX2022016590A (es) | 2020-06-26 | 2023-02-01 | Pfizer | Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. |
| CA3197828A1 (en) | 2020-11-13 | 2022-05-19 | Laurens Kruidenier | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| CA3200256A1 (en) | 2020-12-01 | 2022-06-09 | Rebecca GONSKY | Methods and systems of stratifying inflammatory disease patients |
| CA3202510A1 (en) | 2020-12-21 | 2022-06-30 | Dermot P. Mcgovern | Tl1a therapy compositions and methods of treatment therewith |
| CA3207818A1 (en) | 2021-02-18 | 2022-08-25 | Allison LUO | Anti-tl1a antibody compositions and methods of treatment in the lung |
| MX2023009622A (es) | 2021-02-18 | 2023-08-28 | Prometheus Biosciences Inc | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos. |
| US20240209103A1 (en) | 2021-04-28 | 2024-06-27 | Cedars-Sinai Medical Center | Patient selection methods and kits for therapies targeting tl1a |
| WO2023102071A1 (en) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Microbial metabolites on intestinal inflammation |
| WO2023102051A1 (en) | 2021-12-01 | 2023-06-08 | Cedars-Sinai Medical Center | Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease |
| US20250243289A1 (en) | 2022-01-07 | 2025-07-31 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors |
| US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
-
2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active Active
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 PH PH1/2018/500580A patent/PH12018500580B1/en unknown
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
- 2016-09-16 BR BR112018005407A patent/BR112018005407A8/pt active Search and Examination
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/en active Active
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/en not_active Ceased
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 CA CA2997015A patent/CA2997015A1/en active Pending
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/en active Pending
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt active Search and Examination
- 2016-09-16 HR HRP20201323TT patent/HRP20201323T1/hr unknown
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 SM SM20200500T patent/SMT202000500T1/it unknown
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
-
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
-
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
-
2021
- 2021-11-30 US US17/538,530 patent/US12162946B2/en active Active
-
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
-
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440A1/en active Pending
-
2024
- 2024-11-06 US US18/939,176 patent/US20250179202A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181080A1 (es) | Anticuerpos que se unen especificamente a tl1a | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| AR076018A1 (es) | Anticuerpos multiespecificos especialmente biespecificos | |
| PE20120540A1 (es) | Anticuerpos triespecificos o tetraespecificos | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| AR084315A1 (es) | Anticuerpos anti-notch1 | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| PE20171107A1 (es) | Anticuerpos mejorados contra il-6 | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano |